Dermira (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, today announced several updates related to the upcoming launch and availability of QBREXZA (glycopyrronium) cloth, an anticholinergic indicated for the topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older. QBREXZA was approved by the U.S. Food and Drug Administration (FDA) in June 2018.
As quoted in the press release:
Primary axillary hyperhidrosis, also known as excessive underarm sweating, is a chronic medical skin condition that results in sweating beyond what is needed for normal body temperature regulation. The exact cause is unknown, but it affects nearly 10 million people in the United States, with men and women having similar prevalence. QBREXZA (pronounced kew brex’ zah) is applied directly to the skin and is designed to block sweat production by inhibiting sweat gland activation.
“QBREXZA is the culmination of more than 10 years of clinical development work,” said Tom Wiggans, chairman and chief executive officer of Dermira. “Based on discussions and interactions with dermatologists, we have long recognized that primary axillary hyperhidrosis patients have been underserved due to a lack of innovation and limited treatment options. We are pleased to offer a new therapy to the millions of patients living with this condition.”
QBREXZA is expected to be available in pharmacies nationwide beginning on October 1, 2018.
Click here to read the full press release.
